Skip to main content
Premium Trial:

Request an Annual Quote

Genome Corp. Names SAB, Raises Additional Funds

NEW YORK (GenomeWeb News) – Genome Corp., a six-month old startup developing a new DNA sequencing method, today announced the three founding members of its scientific advisory board. The firm also said that it has raised $250,000 in additional funding.
The new SAB includes Norman Dovichi, an endowed professor of analytical chemistry at the University of Washington and developer of sheath flow detection for capillary electrophoresis; Annelise Barron, an associate professor of bioengineering at Stanford University and developer of sieving matrices for Sanger sequencing; and Patrick Doyle, an associate professor of chemical engineering at the Massachusetts Institute of Technology who is researching DNA migration during electrophoresis.
“We have assembled a truly unique group of advisors to help guide further development of our massively parallel Sanger sequencing technology, said Kevin Ulmer, who co-founded Providence, RI-based Genome Corp. and serves as its president and chief scientific officer.
In addition to announcing the SAB, the firm said that it has received an additional $250,000 in funding from the Slater Technology Fund, bringing its total investment in the company to $500,000 following a similar investment in September.
While most next-generation sequencing platforms combine new chemistries, short reads, and miniaturization, Genome Corp. is betting on factory-style Sanger dideoxy sequencing and read lengths of at least 1,200 base pairs to make sequencing faster and more affordable. The startup believes its approach, which it calls “massively parallel“ Sanger sequencing, will be competitive with existing next-generation technologies.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.